CD44P pGL3 Citations (4)

Originally described in: Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression.
Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, McAllister SS, Jacks T, Weinberg RA Cell. 2008 Jul 11. 134(1):62-73. PubMed Journal

---

Articles Citing CD44P pGL3

Articles
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Canella A, Cordero Nieves H, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F. Oncotarget. 2015 Oct 13;6(31):31134-50. doi: 10.18632/oncotarget.5290. PubMed
BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors. Kim H, Lin Q, Yun Z. Sci Rep. 2019 Jul 4;9(1):9702. doi: 10.1038/s41598-019-46210-y. PubMed
Estradiol-mediated inhibition of Sp1 decreases miR-3194-5p expression to enhance CD44 expression during lung cancer progression. Young MJ, Chen YC, Wang SA, Chang HP, Yang WB, Lee CC, Liu CY, Tseng YL, Wang YC, Sun HS, Chang WC, Hung JJ. J Biomed Sci. 2022 Jan 17;29(1):3. doi: 10.1186/s12929-022-00787-1. PubMed
FOXM1-CD44 Signaling Is Critical for the Acquisition of Regorafenib Resistance in Human Liver Cancer Cells. Wuputra K, Hsiao PJ, Chang WT, Wu PH, Chen LA, Huang JW, Su WL, Yang YH, Wu DC, Yokoyama KK, Kuo KK. Int J Mol Sci. 2022 Jul 14;23(14):7782. doi: 10.3390/ijms23147782. PubMed

If you have published an article using this material, please email us at to have your article added to this page.